Total Payments
$10,441
2024 Payments
$1,800
Companies
5
Transactions
19
Medicare Patients
161
Medicare Billing
$21,345
Payment Breakdown by Category
Consulting$5,325 (51.0%)
Other$2,987 (28.6%)
Research$1,907 (18.3%)
Food & Beverage$222.75 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,325 | 2 | 51.0% |
| Unspecified | $1,907 | 12 | 18.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,800 | 1 | 17.2% |
| Honoraria | $1,187 | 1 | 11.4% |
| Food and Beverage | $222.75 | 3 | 2.1% |
Payments by Type
General
$8,535
7 transactions
Research
$1,907
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $5,708 | 14 | $0 (2022) |
| Genentech, Inc. | $1,800 | 1 | $0 (2024) |
| Mitsubishi Tanabe Pharma America, Inc. | $1,728 | 2 | $0 (2019) |
| AveXis | $1,187 | 1 | $0 (2019) |
| Neurocrine Biosciences, Inc. | $17.89 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,800 | 1 | Genentech, Inc. ($1,800) |
| 2022 | $126.90 | 1 | Biogen, Inc. ($126.90) |
| 2020 | $3,675 | 1 | Biogen, Inc. ($3,675) |
| 2019 | $2,855 | 3 | Mitsubishi Tanabe Pharma America, Inc. ($1,650) |
| 2018 | $1,985 | 13 | Biogen, Inc. ($1,907) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Genentech, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| 09/15/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $126.90 | General |
| 03/09/2020 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,675.00 | General |
| 09/17/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: NEUROLOGY | ||||||
| 09/09/2019 | AveXis | — | Honoraria | Cash or cash equivalent | $1,187.00 | General |
| 05/24/2019 | Mitsubishi Tanabe Pharma America, Inc. | Radicava (Drug) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 12/09/2018 | Mitsubishi Tanabe Pharma America, Inc. | Radicava (Drug) | Food and Beverage | In-kind items and services | $77.96 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 12/07/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $37.09 | Research |
| Study: Single and Multiple Dose Study of BIIB067 in Adults With Amyotrophic Lateral Sclerosis (ALS) | ||||||
| 08/26/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $64.98 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/26/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $53.94 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/26/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $48.80 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/25/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $134.36 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/25/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $64.98 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/25/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $53.94 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/25/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $48.80 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/24/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $638.62 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/24/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $488.08 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/24/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $167.99 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
| 08/24/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $105.00 | Research |
| Study: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | Biogen, Inc. | $1,869 | 11 |
| Single and Multiple Dose Study of BIIB067 in Adults With Amyotrophic Lateral Sclerosis (ALS) | Biogen, Inc. | $37.09 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 27 | 44 | $20,881 | $4,724 |
| 2022 | 1 | 31 | 43 | $18,662 | $4,533 |
| 2021 | 2 | 47 | 72 | $29,071 | $7,119 |
| 2020 | 2 | 56 | 75 | $29,764 | $4,969 |
Total Patients
161
Total Services
234
Medicare Billing
$21,345
Procedure Codes
6
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 27 | 44 | $20,881 | $4,724 | 22.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 31 | 43 | $18,662 | $4,533 | 24.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 33 | 57 | $25,046 | $6,636 | 26.5% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Facility | 2021 | 14 | 15 | $4,025 | $482.73 | 12.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 35 | 53 | $23,384 | $4,214 | 18.0% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Facility | 2020 | 21 | 22 | $6,380 | $754.71 | 11.8% |
About Dr. John Ravits, MD
Dr. John Ravits, MD is a Neurology healthcare provider based in La Jolla, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396858965.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Ravits, MD has received a total of $10,441 in payments from pharmaceutical and medical device companies, with $1,800 received in 2024. These payments were reported across 19 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($5,325).
As a Medicare-enrolled provider, Ravits has provided services to 161 Medicare beneficiaries, totaling 234 services with total Medicare billing of $21,345. Data is available for 4 years (2020–2023), covering 6 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Clinical Neurophysiology, Neuromuscular Medicine
- Location La Jolla, CA
- Active Since 08/16/2006
- Last Updated 08/22/2011
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1396858965
Products in Payments
- Radicava (Drug) $1,728
- INGREZZA (Drug) $17.89
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in La Jolla
Charles Smith, M.d, M.D
Neurology — Payments: $590,505
Neurology $590,505
Dr. Jody Corey-Bloom, Md, Phd, MD, PHD
Neurology — Payments: $452,305
Neurology $452,305
Dr. Jay Rosenberg, M.d, M.D
Neurology — Payments: $216,627
Neurology $216,627
Dr. Christy Jackson, M.d, M.D
Neurology — Payments: $213,127
Neurology $213,127
Dr. Emily Engel, M.d, M.D
Neurology — Payments: $151,871
Neurology $151,871
Dr. Dee Silver, Md, MD
Neurology — Payments: $103,830
Neurology $103,830